The preclinical evaluation of drug-induced cardiotoxicity is an important stage in the drug development process; however, traditional methods for screening drug candidates, such as cardiomyocyte-based ...

Moleculin Biotech (MBRX) has received a Notice of Intent to Grant for the European patent application titled, “Method of Reconstituting ...

Key Laboratory for Molecular Enzymology and Engineering of Ministry of Education, School of Life Science, Jilin University, 2699 Qianjin Street, Changchun 130012, China Edmond H. Fischer Signal ...

Moleculin Biotech, Inc., (Moleculin or the Company), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced it has ...

Key opinion leaders explore approaches to dose modifications or treatment pauses due to side effects, including examples ...

Researchers at St. Jude Children’s Research Hospital identified a panel of 27 serum proteins that accurately predicted ...

genetic variant(s) associated with cardiomyopathy, family history of cardiomyopathy, and those who were exposed to cardiotoxic agents. [Writing Committee Members. J Card Fail. 2022;12a] ...

Such grant will enhance the global exclusivity of Annamycin with the potential to be a next generation, non-cardiotoxic treatment for certain cancers. When issued, the patent claims will cover ...

What multidisciplinary strategies have you found effective in managing the range of side effects associated with ALK inhibitors?

A new fully automated in vivo screening system (AISS) has been developed to transform drug evaluation by enabling rapid, ...

But are the current predictors of cardiotoxic risk adequate? Medscape Oncology, September 26, 2016 Patients Answer Call in Metastatic Breast Cancer Research A nationwide appeal to patients for ...

Preclinical drug evaluation, especially for cardiotoxicity, is a critical stage in the drug development process.